Helminth therapy – local and systemic activity, on example of inflammatory bowel diseases and multiple sclerosis
-
Published:2019-12-02
Issue:
Volume:73
Page:645-653
-
ISSN:0032-5449
-
Container-title:Postępy Higieny i Medycyny Doświadczalnej
-
language:
-
Short-container-title:Postepy Hig Med Dosw
Author:
Maruszewska-Cheruiyot Marta1, Donskow-Łysoniewska Katarzyna1, Doligalska Maria1
Affiliation:
1. Zakład Parazytologii, Instytut Zoologii, Wydział Biologii, Uniwersytet Warszawski, Warszawa
Abstract
Autoimmunological diseases are an increasing problem nowadays in societies. Due to complex etiology, effective therapy against immune disorders is still needed. A promising alternative for the current methods of treatment can be helminthic therapy. Series of tests on animal models as well as clinical studies indicates that parasitic infection can inhibit inflammation in inflammatory bowel diseases and multiple sclerosis. Effectiveness of therapy with helminths, mainly gut nematodes depends on the activity of many compounds released during infection. Despite hopeful results, mechanisms activated by nematodes aren’t explained yet, besides, therapeutically use of live parasites is controversial. Most of studies are focused on searching parasitic factors. The use of this compound in autoimmunological diseases could be an alternative for current medicaments. The aim of current study is summarizing and discussing helminth therapy
of autoimmunological disorder on multiple sclerosis and inflammatory bowel diseases examples
as well as using parasitic compounds as a potential pharmaceutical component.
Publisher
Walter de Gruyter GmbH
Subject
Infectious Diseases,Microbiology (medical)
Reference63 articles.
1. Allen J.E., Maizels R.M.: Diversity and dialogue in immunity tohelminths. Nat. Rev. Immunol., 2011; 11: 375–388 2. Atreya R., Mudter J., Finotto S., Müllberg J., Jostock T., Wirtz S.,Schütz M., Bartsch B., Holtmann M., Becker C., Strand D., Czaja J.,Schlaak J.F., Lehr H.A., Autschbach F. i wsp.: Blockade of interleukin 6 trans signaling suppresses T–cell resistance against apoptosisin chronic intestinal inflammation: evidence in crohn disease andexperimental colitis in vivo. Nat. Med., 2000; 6: 583–588 3. Atreya R., Zimmer M., Bartsch B., Waldner M.J., Atreya I., NeumannH., Hildner K., Hoffman A., Kiesslich R., Rink A.D., Rau T.T.,Rose-John S., Kessler H., Schmidt J., Neurath M.F.: Antibodies againsttumor necrosis factor (TNF) induce T-cell apoptosis in patients withinflammatory bowel diseases via TNF receptor 2 and intestinal CD14+macrophages. Gastroenterology 2011; 141: 2026–2038 4. Balloul J.M., Sondermeyer P., Dreyer D., Capron M., Grzych J.M.,Pierce R.J., Carvallo D., Lecocq J.P., Capron A.: Molecular cloning ofa protective antigen of schistosomes. Nature 1987; 326: 149–153 5. Biancheri P., Di Sabatino A., Ammoscato F., Facciotti F., CaprioliF., Curciarello R., Hoque S.S., Ghanbari A., Joe-Njoku I., Giuffrida P.,Rovedatti L., Geginat J., Corazza G.R., MacDonald T.T.: Absence ofa role for interleukin-13 in inflammatory bowel disease. Eur. J. Immunol.,2014; 44: 370–385
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|